3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
21
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
7
Leukemia, Myeloid, Acute
4
Sarcoma
3
Endometrial Neoplasms
3
Primary Myelofibrosis
2
Neurofibrosarcoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell
2
Glioblastoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Uterine Neoplasms
1
Uterine Diseases
1
Triple Negative Breast Neoplasms
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Interventions
Paclitaxel
6
pembrolizumab
3
Cisplatin
3
Carboplatin
3
Biopsy
3
adavosertib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Doxorubicin
2
ulixertinib
1
tucatinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
sacituzumab govitecan
1
relugolix
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
niraparib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
selinexor
×
1 year
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled